July 31 (Reuters) - Biogen Inc BIIB.O:
BIOGEN -SECOND QUARTER 2025 TOTAL REVENUE $2.6 BILLION
BIOGEN -Q2 NON-GAAP DILUTED EPS $5.47
BIOGEN - OUTLOOK FULL YEAR 2025 NON-GAAP DILUTED EPS $15.50 TO $16.00
BIOGEN -NON-GAAP DILUTED EPS INCLUDES ABOUT ($0.26) IMPACT FROM $47 MILLION OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN QUARTER
BIOGEN -INCREASED EXPECTED FULL YEAR 2025 TOTAL REVENUE TO BE APPROXIMATELY FLAT, AT CONSTANT CURRENCY
BIOGEN -EXPECTS INCREASED COMPETITIVE PRESSURES ON EX- U.S. MS BUSINESS IN SECOND HALF OF 2025
BIOGEN -EXPECTS MINIMAL CONTRACT MANUFACTURING REVENUE IN FOURTH QUARTER OF 2025
BIOGEN -EXPECTS COMBINED NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE AND NON-GAAP SG&A EXPENSE TO TOTAL APPROXIMATELY $4.0 BILLION IN 2025
BIOGEN -2025 FINANCIAL OUTLOOK IS NOT CURRENTLY EXPECTED TO BE MATERIALLY IMPACTED BY POTENTIAL TARIFFS
Further company coverage: BIIB.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.